News
Public · Published
Cantor Fitzgerald maintains AbbVie at Overweight, raises price target to $325 from $290
Cantor Fitzgerald maintained its Overweight rating on AbbVie and raised its price target to $325 from $290, a 12.1% increase. The target implies 10.2% upside from AbbVie's October 30 closing price of $294.89. Five recent analyst targets ranged from $275 to $325.
Published:
Updated:
What happened
Cantor Fitzgerald maintained its Overweight rating on AbbVie and raised its price target to $325 from $290, a 12.1% increase. The target implies 10.2% upside from AbbVie’s October 30 closing price of $294.89. Five recent analyst targets ranged from $275 to $325.
Confirmed
Global impact / market context
The higher target signals that Cantor Fitzgerald sees more potential value in AbbVie shares than before, but it is an analyst estimate rather than a guaranteed outcome. If investors act on the more favorable view, their buying or selling could influence the share price; the article reports no market reaction.
Analyst inference
Recent analyst views are not uniform: the five targets listed span $275 to $325, while ratings include Neutral, Overweight, Outperform and Buy. That spread shows differing expectations about AbbVie’s value; the article provides no company results or industry developments explaining the gap.
Confirmed
What to watch
- Whether other analysts change their AbbVie ratings or price targets, since the article’s five recent targets span $275 to $325 and reflect different views. Analyst inference
- Whether AbbVie’s share price moves toward or away from Cantor Fitzgerald’s $325 target; the article gives a prior close but no subsequent price reaction. Analyst inference
- The article provides no explanation for Cantor Fitzgerald’s higher target, so any stated reasons in later coverage would clarify what assumptions support its view. Analyst inference
Evidence
- Original source link unavailable